At GeneVentiv, we’re blazing a trail. We’re driven by curiosity. We’re fueled by learning expressed as innovation. Our mission is to discover, develop and deliver gene therapies for patients who had no hope of a cure – until now. We are founded on discovery bringing together insights into Adeno Associated Virus (AAV) directed gene therapy, Hemophilia and how to use the common pathway in the clotting cascade to surmount the obstacle of inhibitors. Patients with inhibitors are unable to respond to current therapies and gene therapies in development due to neutralizing antibodies (inhibitors) formed by the body in response to treatment with missing clotting factor. Our goal is to cure inhibitor patients with a single lifetime infusion, not to offer a half measure of weekly injections of a bypass agent. GeneVentiv Therapeutics is Investigational New Drug (IND) Enabling, gene therapy company developing the first effective gene therapy for Hemophilia A and Hemophilia B with or without inhibitors. Join us as we carve a path to a cure for all types of Hemophilia delivered in a single, life changing infusion. To learn more about GeneVentiv, visit www.geneventiv.com.